ATG2A

Across TCGA pan-cancer cohorts, ATG2A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ATG2A’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ATG2A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ATG2A is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, LSCC, and CCRCC are the cancer types where ATG2A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATG2A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	III,IV	−0.317	<.001	8	view →
LSCC	Female	II,III,IV	−0.258	<.001	8	view →
CCRCC	Male	III,IV	−0.260	<.001	7	view →
HNSC	Male	III,IV	+0.143	.008	5	view →
PDAC	Male	II,III,IV	−0.377	.026	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ATG2A–LUAD

Open the LUAD breakdown →